CSBR stock forecast
Our latest prediction for Champions Oncology, Inc.'s stock price was made on the Dec. 19, 2018 when the stock price was at 7.36$.
In the short term (2weeks), CSBR's stock price should outperform the market by 4.69%. During that period the price should oscillate between -10.16% and +18.86%.
In the medium term (3months), CSBR's stock price should outperform the market by 7.17%. During that period the price should oscillate between -22.99% and +41.38%.Get email alerts
About Champions Oncology, Inc.
Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.
At the moment the company generates 23M USD in revenues.
On its last earning announcement, the company reported a loss of None$ per share.
The book value per share is 0.05$
Three months stock forecastDec. 19, 2018
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|